Clinical Trial: NCT04572308
Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Hebei Senlang Biotechnology Inc., Ltd. |
| Information Provided By: | Hebei Senlang Biotechnology Inc., Ltd. |
| Last Update Posted: | 2021-06-29 |
Study Overview
Brief Summary
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (TLBL).
Official Title
Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells
Conditions
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Intervention / Treatment
- Biological: CD7 CAR-T
Other Study ID Numbers
- CD7 CAR-T for T-ALL/T-LBL
Start Date (Actual)
2020-10-01
Primary Completion Date (Actual)
2021-05-30
Study Completion Date (Actual)
2021-05-30
Enrollment (Actual)
20
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Hebei Senlang Biotechnology Inc., Ltd. |
| Information Provided By: | Hebei Senlang Biotechnology Inc., Ltd. |
| Last Update Posted: | 2021-06-29 |
Study Overview
Brief Summary
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (TLBL).
Official Title
Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells
Conditions
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Intervention / Treatment
- Biological: CD7 CAR-T
Other Study ID Numbers
- CD7 CAR-T for T-ALL/T-LBL
Start Date (Actual)
2020-10-01
Primary Completion Date (Actual)
2021-05-30
Study Completion Date (Actual)
2021-05-30
Enrollment (Actual)
20
Study Type
Interventional
Phase
Phase 1